Updated May 24, 2022

Friday, June 3, 2022

1:00                Opening Ceremony– Richard Hillman, President of IANS

1:15 Introduction by Farrah Fawcett Foundation: Alana Stewart, CEO of the Farrah Fawcett Foundation 
Farrah Fawcett Foundation Keynote Address – Treatment of anal cancer, potential use of biological markers and future directions – Karen-Lise Garm Spindler

2:00         Oral Abstract Session - Epidemiology and natural history (non-CME) - Session Chair

Gary Clifford	Predictors of anal high-grade squamous intraepithelial lesions after two years of cytological and histological follow-up in men who have sex with men living with HIV
Sameer V. Gopalani	Incidence trends for HPV-associated anal squamous cell carcinoma in the United States, 1999-2018.
Ramon P. van der Zee	Recent trends in incidence and risk factors of anal cancer in HIV-infected patients in the Netherlands: improved cancer survival in patients diagnosed with anal cancer while in screening

2:35         Novel host determinants of HPV-related diseases can inform new treatment strategies - 
Andrea Lisco

3:15 Coffee Break

3:30 Quick-Hit Abstract Session - Screening and diagnostics and Epidemiology/natural history (non-CME)–   Session Chairs

Danielle R. L. Brogden	The incidences and disease patterns of HPV related cancers in England.
Ben Cardenas	Evaluating the cascade of care for anal cancer screening within a Ryan White HIV/AIDS program clinic
Megan A. Clarke	The Anal Cancer Etiology and Screening (ACES) Study: Design and Baseline Characteristics
Richard Gilson	Screening and early detection to prevent anal cancer (SEPAC): protocol and progress report

3:55 What is happening with anal cancer precursors in low/middle income countries - Valeria Fink

4:30 HPV vaccination among gay, bisexual, and other men who have sex with men – 
Ann Burchell 

5:00 Leveraging existing surveillance systems and creating new ones for anal cancer: Perspectives from the CDC
Mona Saraiya

5:15 Research Review Panel: Large cohort/treatment studies from around the world
Andrew Grulich, Mary Poynten, and Tamzin Cuming

6:15  - 7:15    Opening Reception & Poster Session

Saturday, June 4, 2022

8:00 Working IANS Breakfast 

9:00 Multizonal disease
Michelle Khan and Bernadette Cracchiolo
Session Chair

9:30 ANCHOR Keynote Address: Results of the ANCHOR Study – Joel Palefsky 

10:30 Anal HPV and cancer epidemiology – what’s new – Gary Clifford

10:55 Coffee Break 

11:10 Oral Abstracts Session – Screening and Diagnostics (non-CME)

Camryn Cohen	Automated evaluation of p16/Ki-67 dual stain cytology improves detection of anal precancer in MSM living with HIV
Michael Gaisa	Genital and anal cytology-HPV cotesting results and prediction nomogram for anal high-risk HPC infection in women living with HIV
Fernando Dias Gonçalves Lima	Host cell DNA methylation analysis on minimally invasive anal swabs for the detection of HGAIN and anal cancer in HIV+ MSM
Keith Sigel	Anal Dysplasia Screening in People with HIV Younger than 35

12:00 Lunch on own & Poster Session

1:20 Quick-Hit Abstract Session (non-CME) – Session Chairs

Jonathan Baker	Experience of implementing an HIV preexposure prophylaxis (PrEP) program into an anal dysplasia-focused office.
Eugenio Nelson Cavallari	Reduction of Intraepithelial NK cells Characterizes Anal Dysplasia of Any Grade in HIV+/HPV+ Subjects
Amit Gupta	Awareness of outpatient anal cancer screening among men who have sex with men living with HIV in Canada: The HPV Screening and Vaccine Evaluation (HPV-SAVE) Study
Hillary Johnson	The efficacy of topical Dihydroartemisinin to treat anal dysplasia in mice
Hamish Urquhart	Anal Squamous Cell Carcinoma (ASCC) treated by excision alone results in higher rates of HSIL, and high-risk HPV genotypes when compared to chemoradiotherapy

1:55 IANS Guidelines Update  - Naomi Jay, Elizabeth Stier, Megan Clarke and 
Gary Clifford

2:35 Inside the Guidelines Development Process – Laura Bachmann

2:50 Oral Abstract Session – Screening and Diagnostics (non-CME) - Session Chairs

Tamzin Cuming	The value of high resolution anoscopy (HRA) in the early diagnosis of anal cancer in a high-risk cohort
Yuxin Liu	HPV Testing Differentiates Metastatic Anal Cancer in the Lung from Primary Lung Cancer
Nick Matolka	Performance of 2 different High-Risk HPV assays to predict high-grade squamous intraepithelial lesions (HSIL) on high-resolution anoscopy (HRA).

3:30 Coffee Break

3:45 Natural history and biomarkers of HPV-related cancers: A comparison between anus and cervix –
Nicolas Wentzensen

4:15 ANCHOR Panel Review
Joel Palefsky, Gary Clifford, Andrew Grulich
Chair: Tamzin Cuming

5:00 End of session

6:00                 “A Night at the Opera” Optional Social Activity 

Sunday, June 5, 2022

8:00                 Breakfast/IANS Membership Meeting (IANS Members only)  

9:00 Oral Abstract Session (non-CME) – Session Chair

Naomi Jay	Developing Remote High Resolution Anoscopy Training
Helle Kiellberg Larsen	Risk of anal human papillomavirus infection in kidney transplant recipients compared with immunocompetent controls
Danielle R. L. Brogden	Is local excision alone for early Anal Squamous Cell Carcinoma (ASCC) efficacious in people living with HIV (PLWH)?

9:35 Contemporary patterns in anal cancer incidence and mortality and integration into mathematical modeling to inform guidelines and clinical practice – Ashish Deshmukh

10:15 Coffee Break

10:30 Patient Panel (non-CME)
Rare and Misunderstood: Ten Years Later - Narratives and Perspective on the Anal Cancer Experience with: Daun Ricci, Steven Post, Dr. Stephen Weitzman, John Kneapler and Justine Almada
Session Chair: Mary-Jo Murphy

11:30 Lunch on own 

1:15 Early Anal Cancer Group – J. Michael Berry-Lawhorn
Session Chair

1:30 Expanding HRA Education and Services in the Post-ANCHOR World – Tamzin Cuming, Michelle Khan, Cristina Brickman and Richard Hillman

2:00 10 years of IANS  - Joel, Palefsky, Stephen Goldstone and Naomi Jay

2:30 – 3:00 Wrap up, closing ceremony – Luis Barroso